A Phase 2 study of ONO-4538 in patients with stage IIIB/IV or recurrent squamous NSCLC
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2018
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 12 Feb 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2020.
- 15 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2018.
- 09 Sep 2015 Pooled analysis results of this and other phase II (JapicCTI-No.132073) trial presented at the 16th World Conference on Lung Cancer.